PhAse 1/2 StuDy of Modern ImmunotherApy in BCG-Unresponsive, BCG-RelaPsing, and High-Risk BCG-Naive Non-muscle Invasive UroThelial Carcinoma of the BLADDER
Latest Information Update: 25 Sep 2024
At a glance
- Drugs BCG vaccine (Primary) ; Docetaxel (Primary) ; Durvalumab (Primary) ; Gemcitabine (Primary) ; Tremelimumab (Primary)
- Indications Bladder cancer; Carcinoma; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms ADAPT-BLADDER
- 11 Jan 2023 The treatment arms increased from 6 to 7. Planned patient number decreased from 186 to 55.
- 11 Jan 2023 Planned End Date changed from 1 Dec 2023 to 31 Dec 2025.
- 11 Jan 2023 Planned primary completion date changed from 1 Dec 2022 to 31 Dec 2024.